Bioinformatics analysis of laryngeal squamous cell carcinoma: seeking key candidate genes and pathways

Abstract

Background Laryngeal squamous cell carcinoma (LSCC) is the second most aggressive head and neck squamous cell carcinoma. Although much work has been done to optimize its treatment, patients with LSCC still have poor prognosis. Therefore, figuring out differentially expressed genes (DEGs) contained in the progression of LSCC and employing them as potential therapeutic targets or biomarkers for LSCC is extremely meaningful. Methods Overlapping DEGs were screened from two standalone Gene Expression Omnibus datasets, and Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed. By applying STRING and Cytoscape, a protein–protein network was built, and module analysis was carried out. The hub genes were selected by maximal clique centrality with the CytoHubba plugin of Cytoscape. UALCAN and GEPIA data were examined to validate the gene expression findings. Moreover, the connection of the hub genes with LSCC patient overall survival was studied employing The Cancer Genome Atlas. Then, western blot, qRT-PCR, CCK-8, wound healing and transwell assays were bring to use for further verify the key genes. Results A total of 235 DEGs were recorded, including 83 upregulated and 152 downregulated genes. A total of nine hub genes that displayed a high degree of connectivity were selected. UALCAN and GEPIA databases verified that these genes were highly expressed in LSCC tissues. High expression of the SPP1, SERPINE1 and Matrix metalloproteinases 1 (MMP1) genes was connected to worse prognosis in patients with LSCC, according to the GEPIA online tool. Western blot and qRT-PCR testify SPP1, SERPINE1 and MMP1 were upregulated in LSCC cells. Inhibition of SPP1, SERPINE1 and MMP1 suppressed cell proliferation, invasion and migration. Conclusion The work here identified effective and reliable diagnostic and prognostic molecular biomarkers by unified bioinformatics analysis and experimental verification, indicating novel and necessary therapeutic targets for LSCC.

Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets

“…SERPINE1 is generally classified as a hub or core gene in a wide spectrum of cancer types [ 50 , 118 , 141 , 146 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 ]. For many of the poor outcome cancers, identification of SERPINE1 in the complement of hub or signature genes is a strong indicator of reduced patient survival [ 141 , 184 , 185 , 186 , 187 , 188 , 189 ]. Furthermore, hypoxia is a characteristic of many solid tumors and, in several cancers, a hypoxic TME is associated with patient mortality [ 115 , 190 ].…”

Identification of Novel Prognostic Markers Associated With Laryngeal Squamous Cell Carcinoma Using Comprehensive Analysis

“…LSCC is a leading malignant type of HNSCC. There is an urgent need to identify potential targets for drugs and biomarkers to improve early diagnosis and outcomes (37)(38)(39)(40). A growing body of evidence suggests that solid tumor was stiffer than normal tissue (41).…”

Bioinformatics and systems biology approaches to identify the effects of COVID-19 on neurodegenerative diseases: A review

“…The top 8 (25%) common DEGs were identified as HGs from the network of common DEGs using Cytoscape plugin Cytohubba, with maximal clique centrality (MCC) as the criterion, [35][36][37] and their ranks are presented as color gradients in the graph. The shortest reachable paths between central genes were ranked using Cytohubba's neighbor-neighbor ranking feature.…”